Targeting RAS-mutant Cancers: Is ERK the Key?

Meagan B. Ryan, Channing J. Der, Andrea Wang-Gillam, Adrienne D. Cox

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations


The three RAS genes comprise the most frequently mutated oncogene family in cancer. With significant and compelling evidence that continued function of mutant RAS is required for tumor maintenance, it is widely accepted that effective anti-RAS therapy will have a significant impact on cancer growth and patient survival. However, despite more than three decades of intense research and pharmaceutical industry efforts, a clinically effective anti-RAS drug has yet to be developed. With the recent renewed interest in targeting RAS, exciting and promising progress has been made. In this review, we discuss the prospects and challenges of drugging oncogenic RAS. In particular, we focus on new inhibitors of RAS effector signaling and the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) cascade.

Original languageEnglish
Pages (from-to)183-198
Number of pages16
JournalTrends in Cancer
Issue number3
StatePublished - Nov 1 2015


Dive into the research topics of 'Targeting RAS-mutant Cancers: Is ERK the Key?'. Together they form a unique fingerprint.

Cite this